Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Expands By 36.8%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 53,900 shares, a growth of 36.8% from the February 13th total of 39,400 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 539.0 days.

Inhibitor Therapeutics Price Performance

Shares of INTI remained flat at $0.07 during mid-day trading on Monday. The stock had a trading volume of 13,727 shares, compared to its average volume of 38,647. Inhibitor Therapeutics has a fifty-two week low of $0.04 and a fifty-two week high of $0.14. The stock’s fifty day moving average price is $0.06 and its 200-day moving average price is $0.07. The stock has a market cap of $12.06 million, a P/E ratio of -7.00 and a beta of -0.55.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.